Colon organoid experiments corroborated mucosal repair, crypt structural recovery, Tuft cell expansion, and a shift toward a tissue-restorative type 2 immune profile, characterized by elevated IL-4 and IL-25 and reduced IL-13.<h4>Conclusion</h4>Our findings indicate that BDS treatment in DSS-induced colitis is accompanied by alterations in metabolic pathways, epithelial-immune communication, and cell-type-specific transcriptional programs, which may be relevant to type 2 immune-mediated mucosal repair processes. The gene discussed is IL13; the disease is colitis.